Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry
- PMID: 30808879
- PMCID: PMC6391482
- DOI: 10.1038/s41598-018-37564-w
Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry
Abstract
To evaluate the association between a vessel size index (VSIMRI) derived from dynamic susceptibility contrast (DSC) perfusion imaging using a custom spin-and-gradient echo echoplanar imaging (SAGE-EPI) sequence and quantitative estimates of vessel morphometry based on immunohistochemistry from image-guided biopsy samples. The current study evaluated both relative cerebral blood volume (rCBV) and VSIMRI in eleven patients with high-grade glioma (7 WHO grade III and 4 WHO grade IV). Following 26 MRI-guided glioma biopsies in these 11 patients, we evaluated tissue morphometry, including vessel density and average radius, using an automated procedure based on the endothelial cell marker CD31 to highlight tumor vasculature. Measures of rCBV and VSIMRI were then compared to histological measures. We demonstrate good agreement between VSI measured by MRI and histology; VSIMRI = 13.67 μm and VSIHistology = 12.60 μm, with slight overestimation of VSIMRI in grade III patients compared to histology. rCBV showed a moderate but significant correlation with vessel density (r = 0.42, p = 0.03), and a correlation was also observed between VSIMRI and VSIHistology (r = 0.49, p = 0.01). The current study supports the hypothesis that vessel size measures using MRI accurately reflect vessel caliber within high-grade gliomas, while traditional measures of rCBV are correlated with vessel density and not vessel caliber.
Conflict of interest statement
B.E.; Advisory Board – Hoffman La-Roche; Siemens; Nativis; Medicenna; MedQIA; Bristol Meyers Squibb; Imaging Endpoints; Agios. Paid Consultant – Nativis; MedQIA; Siemens; Hoffman La-Roche; Imaging Endpoints; Medicenna; Agios.
Figures



Similar articles
-
Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.Eur J Radiol. 2016 Jun;85(6):1147-56. doi: 10.1016/j.ejrad.2016.03.020. Epub 2016 Mar 22. Eur J Radiol. 2016. PMID: 27161065
-
Comparison of the Effect of Vessel Size Imaging and Cerebral Blood Volume Derived from Perfusion MR Imaging on Glioma Grading.AJNR Am J Neuroradiol. 2016 Jan;37(1):51-7. doi: 10.3174/ajnr.A4477. Epub 2015 Sep 17. AJNR Am J Neuroradiol. 2016. PMID: 26381565 Free PMC article.
-
Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging.Neuroradiology. 2018 Jan;60(1):43-50. doi: 10.1007/s00234-017-1942-8. Epub 2017 Oct 31. Neuroradiology. 2018. PMID: 29090331
-
MR evaluation of vessel size imaging of human gliomas: Validation by histopathology.J Magn Reson Imaging. 2015 Oct;42(4):1117-25. doi: 10.1002/jmri.24864. Epub 2015 Feb 16. J Magn Reson Imaging. 2015. PMID: 25683112
-
Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.Neuroimage Clin. 2018 Jul 5;20:51-60. doi: 10.1016/j.nicl.2018.07.001. eCollection 2018. Neuroimage Clin. 2018. PMID: 30069427 Free PMC article. Review.
Cited by
-
MRI biomarkers in neuro-oncology.Nat Rev Neurol. 2021 Aug;17(8):486-500. doi: 10.1038/s41582-021-00510-y. Epub 2021 Jun 20. Nat Rev Neurol. 2021. PMID: 34149051 Review.
-
Challenges and opportunities for advanced neuroimaging of glioblastoma.Br J Radiol. 2023 Jan 1;96(1141):20211232. doi: 10.1259/bjr.20211232. Epub 2022 Oct 14. Br J Radiol. 2023. PMID: 36062962 Free PMC article. Review.
-
Rapid simultaneous estimation of relaxation rates using multi-echo, multi-contrast MRI.Magn Reson Imaging. 2024 Oct;112:116-127. doi: 10.1016/j.mri.2024.07.007. Epub 2024 Jul 4. Magn Reson Imaging. 2024. PMID: 38971264
-
Standardized brain tumor imaging protocols for clinical trials: current recommendations and tips for integration.Front Radiol. 2023 Dec 13;3:1267615. doi: 10.3389/fradi.2023.1267615. eCollection 2023. Front Radiol. 2023. PMID: 38152383 Free PMC article. Review.
-
Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response.J Neurooncol. 2025 Jul;173(3):583-594. doi: 10.1007/s11060-025-05019-8. Epub 2025 Apr 14. J Neurooncol. 2025. PMID: 40227555 Free PMC article.